Palisade Bio, Inc.
PALI
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$1.91
FAIR PRICE
$1.39
MARGIN
$0.52
P/E Ratio
N/A
Div. Yield
N/A
ROE
-240.7%
Market Cap
$282M
Small-cap
COMING SOON
Get notified when PALI's fair price changes
Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.
iOS and Android · Free tier available
KEY FACTS
CEO
J. D. Finley
COUNTRY
US
HEADQUARTERS
Carlsbad
SECTOR
Healthcare
EXCHANGE
NASDAQ
METHODOLOGY
How we calculate PALI's fair price
Palisade Bio, Inc.'s fair price of $1.39 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%). At the current market price of $1.91, PALI trades 27.2% above its calculated fair value.
DCF MODEL · 50%
Discounted cash flow analysis based on projected free cash flows, discounted at a rate reflecting PALI's risk profile.
RELATIVE · 30%
Comparing PALI's valuation multiples against Healthcare peers.
ANALYST · 20%
Aggregated analyst price targets for PALI, weighted by recency and analyst accuracy.
POWERED BY BULIOS
Get full analysis, financials, and AI insights for PALI.
Explore on BuliosFAQ
What is the fair price of PALI?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Palisade Bio, Inc. is $1.39. At the current market price of $1.91, PALI trades 27.2% above its calculated fair value.
Is PALI overvalued or undervalued?+
Palisade Bio, Inc. is currently overvalued based on our valuation model. The stock trades at $1.91, which is 27.2% above the fair price of $1.39.
How often is PALI's fair price updated?+
We update fair price calculations for PALI daily after market close. The current fair price of $1.39 incorporates the latest market data and sector multiples.
What factors affect PALI's fair price calculation?+
PALI's fair price of $1.39 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -240.7%.
Is PALI a good buy right now?+
At $1.91, PALI trades 27.2% above our fair value estimate of $1.39. The stock is currently overvalued. ROE stands at -240.7% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does PALI pay dividends?+
PALI does not currently pay a dividend.